InvestSMART

BCAL Diagnostics Limited (ASX:BDX)

ALERT: Price-sensitive ASX Announcement for BDX
Current share price for BDX : $0.075 -0.02 (-21.05%)+
Announcement
Release
26 Mar 2026 9:19AM
Price at Release
$0.095
Full Release
download
Summary
BCAL Diagnostics Limited (ASX: BDX), an Australian healthcare company, is rapidly expanding the commercial availability of its Avantect Pancreatic and Ovarian early detection blood tests across Australia. Initially launched in January 2026 at the Sydney Breast Clinic, these tests are now accessible through Sonic Healthcare's pathology collection centers in New South Wales, Victoria, and Queensland, with national distribution secured via Healius Pathology Network. This rollout is part of BCAL's strategy to enhance early cancer detection using cell-free DNA-based blood tests that leverage genomic and epigenomic analysis, supplemented by machine learning. The national rollout aims to improve clinical outcomes by facilitating earlier detection of cancers, thereby allowing more effective treatment options. BCAL also collaborates with Sonic Healthcare to enhance patient access to its blood-based cancer diagnostics portfolio, including BREASTEST plus.
Key Points
  • National rollout of Avantect Pancreatic and Ovarian blood tests
  • Tests available through Sonic Healthcare and Healius Pathology Network
  • Collaboration with Sonic Healthcare to expand cancer diagnostics access
  • Avantect designed for early detection of pancreatic and ovarian cancers
  • Incorporation of genomic and epigenomic analysis with machine learning
  • Initial launch in January 2026 at Sydney Breast Clinic
  • BCAL Diagnostics Limited listed on ASX as BDX
  • Enhancement of early cancer detection capabilities
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.